#SFHS2608203VNotice Relating to the Prices of Pharmaceutical Specialties Published Under Article L. 162-16-6 of the Social Security Code
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This law updates the price and cost responsibility of a specific pharmaceutical product called LOARGYS 5MG/ML INJ FL0,4ML in France. The pharmaceutical company IMMEDICA PHARMA A.B is involved, and the updated pricing will be effective two weeks after its announcement in the official French legal gazette. Healthcare facilities purchasing these pharmaceuticals need to adhere to the new pricing structures.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Updated price for LOARGYS 5MG/ML INJ FL0,4ML
- Effective two weeks post-official announcement
- Involves IMMEDICA PHARMA A.B and healthcare facilities
Obligations
What this law requires
Healthcare facilities must apply the new pricing structure for LOARGYS 5MG/ML INJ FL0,4ML with a responsibility tariff (tarif de responsabilité) of €4,500.00 per UCD and a maximum sales price of €4,500.00 per UCD
IMMEDICA PHARMA FRANCE SARL must implement the updated pricing effective fifteen days after publication in the official French legal gazette (Journal officiel de la République française)
Pricing and cost responsibility must be applied as per the convention between the economic committee for health products (comité économique des produits de santé) and IMMEDICA PHARMA A.B under Article L. 162-16-6 of the Social Security Code
The effective date of implementation is the fifteenth day following publication in the Journal officiel de la République française